-
1دورية أكاديمية
المؤلفون: Stephan Ursprung (8507466), Helen Mossop (5950922), Ferdia A. Gallagher (119185), Evis Sala (3485), Richard Skells (11728121), Jamal A. N. Sipple (11728124), Thomas J. Mitchell (8723835), Anita Chhabra (11728127), Kate Fife (7457435), Athena Matakidou (222418), Gemma Young (11728130), Amanda Walker (4677124), Martin G. Thomas (11728133), Mireia Crispin Ortuzar (11728136), Mark Sullivan (459776), Andrew Protheroe (8508), Grenville Oades (11728139), Balaji Venugopal (11728142), Anne Y. Warren (8889656), John Stone (4334065), Tim Eisen (244447), James Wason (3457430), Sarah J. Welsh (11607930), Grant D. Stewart (11728145)
مصطلحات موضوعية: Medicine, Cell Biology, Pharmacology, Biotechnology, Immunology, Cancer, Clinical trial protocol [MeSH], Clear cell renal cell carcinoma [MeSH], Phase II clinical trial [MeSH], Bayesian adaptive trial, Olaparib [MeSH], Cediranib [MeSH], Durvalumab [MeSH], Window-of-opportunity, Neoadjuvant therapy [MeSH]
-
2دورية أكاديمية
المؤلفون: Stephan Ursprung (8507466), Helen Mossop (5950922), Ferdia A. Gallagher (119185), Evis Sala (3485), Richard Skells (11728121), Jamal A. N. Sipple (11728124), Thomas J. Mitchell (8723835), Anita Chhabra (11728127), Kate Fife (7457435), Athena Matakidou (222418), Gemma Young (11728130), Amanda Walker (4677124), Martin G. Thomas (11728133), Mireia Crispin Ortuzar (11728136), Mark Sullivan (459776), Andrew Protheroe (8508), Grenville Oades (11728139), Balaji Venugopal (11728142), Anne Y. Warren (8889656), John Stone (4334065), Tim Eisen (244447), James Wason (3457430), Sarah J. Welsh (11607930), Grant D. Stewart (11728145)
مصطلحات موضوعية: Medicine, Cell Biology, Pharmacology, Biotechnology, Immunology, Cancer, Clinical trial protocol [MeSH], Clear cell renal cell carcinoma [MeSH], Phase II clinical trial [MeSH], Bayesian adaptive trial, Olaparib [MeSH], Cediranib [MeSH], Durvalumab [MeSH], Window-of-opportunity, Neoadjuvant therapy [MeSH]
-
3صورة
المؤلفون: Marion Tardieu (11966324), Yulia Lakhman (11966327), Lakhdar Khellaf (11966330), Maida Cardoso (5040383), Olivia Sgarbura (11966333), Pierre-Emmanuel Colombo (3422483), Mireia Crispin-Ortuzar (11966336), Evis Sala (3485), Christophe Goze-Bac (845088), Stephanie Nougaret (11966339)
مصطلحات موضوعية: Cancer, Cancer Cell Biology, Cancer Diagnosis, Cancer Genetics, Cancer Therapy (excl. Chemotherapy and Radiation Therapy), Chemotherapy, Haematological Tumours, Molecular Targets, Radiation Therapy, Solid Tumours, Oncology and Carcinogenesis not elsewhere classified, ovarian cancer, MRI, radiomics, machine learning, histology
-
4صورة
المؤلفون: Marion Tardieu (11966324), Yulia Lakhman (11966327), Lakhdar Khellaf (11966330), Maida Cardoso (5040383), Olivia Sgarbura (11966333), Pierre-Emmanuel Colombo (3422483), Mireia Crispin-Ortuzar (11966336), Evis Sala (3485), Christophe Goze-Bac (845088), Stephanie Nougaret (11966339)
مصطلحات موضوعية: Cancer, Cancer Cell Biology, Cancer Diagnosis, Cancer Genetics, Cancer Therapy (excl. Chemotherapy and Radiation Therapy), Chemotherapy, Haematological Tumours, Molecular Targets, Radiation Therapy, Solid Tumours, Oncology and Carcinogenesis not elsewhere classified, ovarian cancer, MRI, radiomics, machine learning, histology
-
5
المؤلفون: Stephan Ursprung (8507466), Helen Mossop (5950922), Ferdia A. Gallagher (119185), Evis Sala (3485), Richard Skells (11728121), Jamal A. N. Sipple (11728124), Thomas J. Mitchell (8723835), Anita Chhabra (11728127), Kate Fife (7457435), Athena Matakidou (222418), Gemma Young (11728130), Amanda Walker (4677124), Martin G. Thomas (11728133), Mireia Crispin Ortuzar (11728136), Mark Sullivan (459776), Andrew Protheroe (8508), Grenville Oades (11728139), Balaji Venugopal (11728142), Anne Y. Warren (8889656), John Stone (4334065), Tim Eisen (244447), James Wason (3457430), Sarah J. Welsh (11607930), Grant D. Stewart (11728145)
مصطلحات موضوعية: Medicine, Cell Biology, Pharmacology, Biotechnology, Immunology, Cancer, Clinical trial protocol [MeSH], Clear cell renal cell carcinoma [MeSH], Phase II clinical trial [MeSH], Bayesian adaptive trial, Olaparib [MeSH], Cediranib [MeSH], Durvalumab [MeSH], Window-of-opportunity, Neoadjuvant therapy [MeSH]